Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Current medicinal chemistry - 1 Jan 2011

Gnanasambandan K, Sayeski P P

Abstract excerpt

Jak2 is a non-receptor tyrosine kinase that is involved in the control of cellular growth and proliferation. Due to its significant role in hematopoiesis, Jak2 is a frequent target for mutations in cancer, especially myeloid leukemia, lymphoid leukemia and the myeloproliferative neoplasms (MPN). These mutations are common amongst different populations all over the world and there is a great deal of effort to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Binding Sites
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Models, Molecular

Share to Protein Structure, Tertiary

Share to Proto-Oncogene Proteins c-abl

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 21864276
DOI: 10.2174/092986711797379267
PMCID: PMC4943318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.PMID 21864276Read ↗

Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.Semantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

The use of structural biology in Janus kinase targeted drug discovery.Semantic proximity Read ↗

Insight into Janus kinases specificity: From molecular architecture to cancer therapeuticsSemantic proximity Read ↗

Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.Semantic proximity Read ↗

New insights into the structure and function of the pseudokinase domain in JAK2.Semantic proximity Read ↗

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.Semantic proximity Read ↗

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.Semantic proximity Read ↗

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.